GSK (MEX:GSKN) Total Equity: MXN418,888 Mil (As of Mar. 2026)


MEX:GSKN GSK PLC MEX:GSKN
73 GF Score
Price MXN901.11
GF Value MXN818.82
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GSK Total Equity?

GSK MEX:GSKN 73 Total Equity is MXN418,888 Mil as of Mar. 2026. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review.

GSK's total equity for the quarter that ended in Mar. 2026 was MXN418,888 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

GSK Total Equity Historical Data

* Premium members only.

The historical data trend for GSK's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Total Equity Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 582,193.87 239,746.18 274,918.36 345,028.69 384,603.68

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 360,899.56 366,722.30 390,483.57 384,603.68 418,887.60
MEX:GSKN
73GF Score
GSK PLC MEX:GSKN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

GSK's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1473189.254-1088585.573
=384,604

GSK's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1511597.088-1092709.489
=418,888

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of MXN418,888 Mil mean?
GSK (MEX:GSKN) has a Total Equity of MXN418,888 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for GSK and its competitors.
Is GSK's Total Equity too high?
GSK's current Total Equity is MXN418,888 Mil. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's Total Equity compare to LLY and JNJ?
GSK's Total Equity of MXN418,888 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for GSK and its competitors. GSK's current Total Equity is MXN418,888 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current Total Equity is MXN418,888 Mil. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Total Equity is MXN418,888 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSKN) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82. GuruFocus considers GSK to be Fairly Valued.

Key valuation signals for MEX:GSKN:

  • Total Equity: MXN418,888 Mil
  • GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for MEX:GSKN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN901.11
Price
MXN818.82
GF Value